DMAC vs. MRVI, ELVN, PAHC, ZYME, ABCL, REPL, COLL, RCKT, EOLS, and PHVS
Should you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Maravai LifeSciences (MRVI), Enliven Therapeutics (ELVN), Phibro Animal Health (PAHC), Zymeworks (ZYME), AbCellera Biologics (ABCL), Replimune Group (REPL), Collegium Pharmaceutical (COLL), Rocket Pharmaceuticals (RCKT), Evolus (EOLS), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry.
DiaMedica Therapeutics vs.
Maravai LifeSciences (NASDAQ:MRVI) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership, community ranking and valuation.
DiaMedica Therapeutics has lower revenue, but higher earnings than Maravai LifeSciences. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.
DiaMedica Therapeutics received 31 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. Likewise, 62.84% of users gave DiaMedica Therapeutics an outperform vote while only 62.63% of users gave Maravai LifeSciences an outperform vote.
Maravai LifeSciences currently has a consensus target price of $10.28, suggesting a potential upside of 150.15%. DiaMedica Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 7.53%. Given Maravai LifeSciences' higher probable upside, research analysts clearly believe Maravai LifeSciences is more favorable than DiaMedica Therapeutics.
In the previous week, DiaMedica Therapeutics had 1 more articles in the media than Maravai LifeSciences. MarketBeat recorded 5 mentions for DiaMedica Therapeutics and 4 mentions for Maravai LifeSciences. DiaMedica Therapeutics' average media sentiment score of 0.63 beat Maravai LifeSciences' score of 0.27 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.
Maravai LifeSciences has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500.
DiaMedica Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -81.13%. Maravai LifeSciences' return on equity of -6.61% beat DiaMedica Therapeutics' return on equity.
50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 0.6% of Maravai LifeSciences shares are owned by company insiders. Comparatively, 7.2% of DiaMedica Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
DiaMedica Therapeutics beats Maravai LifeSciences on 10 of the 17 factors compared between the two stocks.
Get DiaMedica Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DiaMedica Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:DMAC) was last updated on 2/22/2025 by MarketBeat.com Staff
Free DMAC Stock Alerts